News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
517,755 Results
Type
Article (11335)
Company Profile (143)
Press Release (506275)
Multimedia
Podcasts (82)
Webinars (9)
Section
Business (174647)
Career Advice (380)
Deals (26936)
Drug Delivery (80)
Drug Development (56694)
Employer Resources (18)
FDA (10815)
Job Trends (9173)
News (252540)
Policy (21493)
Tag
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (653)
Accelerated approval (33)
ADA (30)
Adcomms (5)
Allergies (113)
Alliances (34899)
ALS (134)
Alzheimer's disease (1086)
Antibody-drug conjugate (ADC) (323)
Approvals (11502)
Artificial intelligence (406)
ASCO (173)
Autoimmune disease (235)
Automation (32)
Bankruptcy (277)
Belgium (1)
Best Places to Work (7390)
BIO (37)
Biologics (9)
BIOSECURE Act (2)
Biosimilars (154)
BioSpace Insights (31)
Biotechnology (94)
Bispecific (1)
Bladder cancer (152)
Brain cancer (48)
Breast cancer (548)
Cancer (4118)
Cardiovascular disease (322)
Career advice (313)
Career pathing (5)
CAR-T (189)
CDC (9)
CDMO (50)
Celiac Disease (1)
Cell therapy (540)
Cervical cancer (37)
Clinical research (51236)
Collaboration (1424)
Commercialization (3)
Compensation (1542)
Complete response letters (48)
COVID-19 (994)
CRISPR (73)
C-suite (875)
Cystic fibrosis (98)
Data (6299)
Decentralized trials (1)
Denatured (7)
Depression (115)
Dermatology (74)
Diabetes (506)
Diagnostics (4509)
Digital health (44)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (198)
Drug pricing (110)
Drug shortages (29)
Duchenne muscular dystrophy (191)
Earnings (76734)
Editorial (21)
Employer branding (2)
Employer resources (19)
Events (91863)
Executive appointments (770)
FDA (13839)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (25)
Funding (1125)
Gene editing (143)
Generative AI (28)
Gene therapy (377)
GLP-1 (905)
Government (2421)
Grass and pollen (3)
Guidances (309)
Healthcare (10569)
Hematology (98)
HIV (61)
Huntington's disease (26)
IgA nephropathy (71)
Immunology and inflammation (135)
Immuno-oncology (72)
Indications (175)
Infectious disease (1207)
Inflammatory bowel disease (137)
Inflation Reduction Act (9)
Influenza (90)
Intellectual property (274)
Interviews (49)
IPO (12929)
IRA (22)
Job creations (2140)
Job search strategy (295)
JPM (19)
Kidney cancer (21)
Labor market (15)
Layoffs (118)
Leadership (5)
Legal (5542)
Licensing (19)
Liver cancer (55)
Longevity (20)
Lung cancer (580)
Lymphoma (287)
Machine learning (33)
Management (5)
Manufacturing (715)
Marketing (8)
MASH (151)
Medical affairs (2)
Medical device (9452)
Medtech (9622)
Mergers & acquisitions (15131)
Metabolic disorders (1354)
mRNA (91)
Multiple sclerosis (115)
NASH (8)
Neurodegenerative disease (269)
Neuropsychiatric disorders (50)
Neuroscience (2085)
Neurotech (1)
NextGen: Class of 2026 (3383)
Non-profit (1254)
Now hiring (40)
Obesity (679)
Opinion (37)
Ovarian cancer (179)
Pain (188)
Pancreatic cancer (228)
Parkinson's disease (222)
Partnered (14)
Patents (537)
Patient recruitment (587)
Patient selection (3)
Peanut (40)
People (43296)
Peptides (5)
Pharmaceutical (32)
Pharmacy benefit managers (14)
Phase 1 (16137)
Phase 2 (22653)
Phase 3 (16024)
Pipeline (8352)
Policy (104)
Postmarket research (1718)
Preclinical (6778)
Press Release (37)
Prostate cancer (224)
Psychedelics (18)
Radiopharmaceuticals (228)
Rare diseases (679)
Real estate (3270)
Recruiting (9)
Regenerative medicine (2)
Regulatory (17306)
Reports (29)
Research institute (736)
Resumes & cover letters (58)
Rett syndrome (44)
RNA editing (8)
RSV (51)
Schizophrenia (126)
Series A (208)
Series B (143)
Service/supplier (6)
Sickle cell disease (80)
Special edition (6)
Spinal muscular atrophy (103)
Sponsored (9)
Startups (2178)
Stomach cancer (3)
Supply chain (83)
Tariffs (31)
The Weekly (73)
Vaccines (471)
Venture capital (44)
Weight loss (492)
Women's health (99)
Worklife (2)
Date
Today (52)
Last 7 days (301)
Last 30 days (1537)
Last 365 days (20758)
2026 (14948)
2025 (20819)
2024 (24654)
2023 (28131)
2022 (37233)
2021 (40432)
2020 (36572)
2019 (26040)
2018 (19634)
2017 (20355)
2016 (19414)
2015 (25737)
2014 (22661)
2013 (18920)
2012 (20953)
2011 (21198)
2010 (21022)
Location
Africa (297)
Alabama (81)
Alaska (4)
Arizona (316)
Arkansas (11)
Asia (20026)
Australia (2705)
California (12552)
Canada (3852)
China (647)
Colorado (512)
Connecticut (445)
Delaware (232)
Europe (32906)
Florida (1898)
Georgia (398)
Hawaii (3)
Idaho (49)
Illinois (768)
India (71)
Indiana (410)
Iowa (24)
Japan (457)
Kansas (104)
Kentucky (33)
Louisiana (29)
Maine (28)
Maryland (1307)
Massachusetts (8380)
Michigan (318)
Minnesota (592)
Mississippi (4)
Missouri (99)
Montana (21)
Nebraska (17)
Nevada (126)
New Hampshire (69)
New Jersey (2990)
New Mexico (12)
New York (2974)
North Carolina (1372)
North Dakota (4)
Northern California (6332)
Ohio (326)
Oklahoma (16)
Oregon (20)
Pennsylvania (2396)
Puerto Rico (22)
Rhode Island (33)
South America (486)
South Carolina (79)
South Dakota (1)
Southern California (5189)
Tennessee (132)
Texas (2081)
United States (41445)
Utah (378)
Vermont (2)
Virginia (168)
Washington D.C. (41)
Washington State (974)
West Virginia (1)
Wisconsin (77)
Wyoming (1)
517,755 Results for "novo nordisk canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
C-suite
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall business strategy.
September 14, 2026
·
3 min read
·
Annalee Armstrong
Weight loss
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.
August 21, 2026
·
2 min read
·
Nick Paul Taylor
GLP-1
Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’
Analysts will be watching as a generic version of semaglutide—marketed by Novo Nordisk as Wegovy for weight loss—launches in Canada as a test case for future price erosion in the U.S.
April 29, 2026
·
3 min read
·
Annalee Armstrong
cardiovascular disease
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile cardiovascular flops to six over nine weeks.
September 8, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Novo Nordisk A/S - share repurchase programme - September 21, 2026
September 21, 2026
·
2 min read
Sickle cell disease
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.
July 21, 2026
·
2 min read
·
Gabrielle Masson
Earnings
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
Novo Nordisk’s shares fell 6% on Tuesday afternoon after its second quarter earnings report showed a slight miss for the Wegovy pill vs. consensus.
August 4, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Novo Nordisk A/S - share repurchase programme - September 14, 2026
September 14, 2026
·
2 min read
Obesity
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.
August 19, 2026
·
7 min read
·
Tristan Manalac
Press Releases
Novo Nordisk A/S - share repurchase programme - September 7, 2026
September 7, 2026
·
2 min read
1 of 51,776
Next
